6505--VA Loma Linda Radiopharmaceuticals
ID: 36C26224Q1356Type: Combined Synopsis/Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OF262-NETWORK CONTRACT OFFICE 22 (36C262)Gilbert, AZ, 85297, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/78d885b77d48475b88c13b4c15a69298/view
Timeline
    Description

    The Department of Veterans Affairs (VA) seeks proposals for a firm-fixed-price contract to supply radiopharmaceuticals to the VA Loma Linda Healthcare System. The goal is to procure a comprehensive range of these specialized pharmaceuticals for use in nuclear medicine and imaging services over a four-year period, with the potential for a one-year extension.

    The VA aims to purchase a diverse array of products, including FDG, NAF, Sodium Iodine, In-111 Pentetreotide, and Tc-99m-based formulations, among others. These medications are subject to stringent quality and packaging regulations and must be delivered within specific timelines.

    The scope of work for the awardee will involve fulfilling orders and delivering the requested quantities of these pharmaceuticals to the healthcare system. Attention to detail is paramount, given the specialized nature of the products and their applications.

    Eligible applicants should possess the capabilities and expertise to meet the VA's specialized pharmaceutical needs. Experience in the industry and a track record of adhering to high-quality standards are essential.

    Funding for this contract is estimated at up to $5 million, encompassing the base year and optional periods. The contract type is firm-fixed-price. Offerors must submit their quotes, including pricing structures, by the extended response deadline of 8 August 2024, 10:00 AM Pacific Time, as stated in Amendment 0002.

    The VA will evaluate applications based on their ability to meet the specified pharmaceutical requirements, with consideration given to product quality, adherence to technical specifications, and cost effectiveness.

    For clarification or questions, interested parties can contact Contract Specialist Hestia Sim at Hestia.Sim@va.gov.

    This opportunity seeks to ensure a reliable supply of essential radiopharmaceuticals for the VA Loma Linda Healthcare System, emphasizing careful consideration of the product's unique nature and associated regulations.

    Point(s) of Contact
    Hestia SimContract Specialist
    Hestia.Sim@va.gov
    Files
    Title
    Posted
    36C26224Q1356.docx
    The Department of Veterans Affairs seeks to establish a single firm-fixed-price contract for a base year and four optional years for the supply of radiopharmaceuticals to the VA Loma Linda Healthcare System. The goal is to procure a diverse range of radioactive pharmaceuticals, including FDG, NAF, Sodium Iodine, In-111 Pentetreotide, and various Tc-99m-based products, among others, for use in nuclear medicine and imaging services. These pharmaceuticals must adhere to quality and packaging standards and be delivered to the healthcare system within specified timeframes. The estimated total value of the contract is up to $5 million. Offerors must submit their quotes by the response deadline for consideration. Key dates include a question submission deadline of July 17, 2024, and a response deadline of July 22, 2024.
    36C26224Q1356 0001.docx
    The Department of Veterans Affairs issues an amendment extending the response deadline for its previous solicitation (36C26224Q1356) related to radiopharmaceuticals. The focus is on clarifying requirements, especially for Tc99m-based products, and addressing vendor questions. Duplications noted are not errors; the VA specifically requires both HEU and non-HEU variants. Vendors must adhere to specified quantities and quality standards, especially for sentinel node detection in melanoma patients. The VA will accept substitutes for Lymphoseek, but they must meet stringent requirements. This amendment doesn't alter the original solicitation's terms, merely extending the response date. The initial solicitation sought bids for a comprehensive range of radiopharmaceuticals, with response deadline now confirmed as July 30th, 2024.
    36C26224Q1356 0002.docx
    The Department of Veterans Affairs issues an amendment extending the response deadline for its previous combined solicitation 36C26224Q1356. The focus remains on procuring radiopharmaceuticals for the VA Loma Linda Healthcare System. Offerors must carefully review the updated B.3 Price/Cost Schedule, which revises the quantities and provides a clear breakdown of the requested radiopharmaceuticals. They are required to resubmit their offers with estimated total costs for a four-year base period, along with an additional option year. All other terms and conditions stay the same, and the new response deadline is now 8 August 2024, 10:00 AM Pacific Time.
    B.3 PriceCost Schedule_updated.xlsx
    The government seeks to procure a substantial supply of radiopharmaceuticals, a specialized field within pharmaceuticals, for various medical purposes. These products are primarily used in nuclear medicine and include FDG, NAF, Sodium Iodine, Iodide, and several others, with specific activities and quantities listed. The request also includes related dispensing fees and balloons for H Pylori breath tests. The estimated total cost is provided, broken down into base year and optional years' pricing, with quantities estimated for each year. This procurement aims to ensure an adequate supply of these specialized pharmaceuticals, and contractors will likely be responsible for fulfilling these orders and delivering the specified quantities to the government. The evaluation of proposals will likely focus on factors such as product quality and adherence to technical specifications, as well as pricing structures.
    B.3 PriceCost Schedule.xlsx
    Lifecycle
    Title
    Type
    6505--VA Loma Linda Radiopharmaceuticals
    Currently viewing
    Combined Synopsis/Solicitation
    Similar Opportunities
    6525--Radiopharmaceuticals and Associated Supplies
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified vendors to provide radiopharmaceuticals and associated supplies for the Salem VA Medical Center in Virginia. This procurement aims to establish a contract for nuclear medicine services, including a base year and four option years, with a requirement for timely delivery of various radiopharmaceuticals within two hours of notification. The goods and services are critical for medical imaging and treatment, ensuring that the facility can effectively serve its veteran population. Interested vendors must respond by 9:00 AM EDT on September 9, 2024, with detailed information about their capabilities and qualifications, and can contact Contract Specialist James Risbon at james.risbon@va.gov for further inquiries.
    6505--Pylarify(Piflufolastat F18 Injection) for DC VAMC
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking qualified sources to provide Pylarify (Piflufolastat F18 Injection) for the DC Veterans Affairs Medical Center (DC VAMC) in Washington, D.C. The procurement involves the delivery of this radiopharmaceutical to the Nuclear Medicine Section of the Radiology Service, with a base contract period of one year and four optional one-year extensions. This product is critical for diagnostic imaging and treatment in nuclear medicine, and the contractor must ensure compliance with various regulatory standards while providing online ordering capabilities and timely deliveries. Interested parties should submit their responses, including company information and capabilities, to Ryan Singletary at Ryan.Singletary@va.gov by September 16, 2024, at 3:00 PM EST.
    6505--Plyarify - Radiopharmaceuticals
    Active
    Veterans Affairs, Department Of
    Special Notice: VETERANS AFFAIRS, DEPARTMENT OF is seeking to procure Plyarify - Radiopharmaceuticals. Plyarify is a radioactive diagnostic agent used for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. The procurement involves the preparation and delivery of F-18 Piflufolastat (Pylarify) doses performed at a contractor facility and delivered to the PET/CT Service at VA Connecticut Healthcare in West Haven, CT. Deliveries will be made Monday through Friday between 7:00 am and 3:00 pm. Only vendors within a 60-mile radius of VA Connecticut need to respond to this RFQ. The contractor's personnel must be licensed in a State, Territory, or Commonwealth of the United States or the District of Columbia. The contractor will bill on a monthly basis, itemizing all services rendered. The services covered by this contract shall be furnished by the contractor Monday through Friday, 7:00 am - 3:00 pm. There is no restriction on the number of orders or deliveries required per day. The delivery location is VA Connecticut Healthcare System in West Haven, CT. Interested parties must submit their capability to fulfill the requirement in writing by Monday, July 15, 2024, at 12 pm EST time.
    Notice of Intent to Sole Source a Blanket Purchase Agreement (BPA) for a variety of radiopharmaceuticals (radiology medications) for use in the Nuclear Medicine Division at Naval Medical Center San Diego
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), intends to award a sole source Blanket Purchase Agreement (BPA) to RLS (USA), Inc. for the procurement of various radiopharmaceuticals required by the Nuclear Medicine Division at Naval Medical Center San Diego (NMCSD). This five-year contract will cover the supply of 31 essential radiopharmaceuticals, four additional medications, and expedited delivery services, all of which are critical for diagnostic imaging and treatment in Nuclear Medicine. Due to the radioactive nature and short shelf-life of these medications, strict adherence to transportation regulations is necessary, with deliveries occurring daily. Interested vendors may submit capability statements by September 10, 2024, to Jennifer Collins at jennifer.e.collins23.civ@health.mil, as this opportunity does not involve competitive proposals.
    6505--Levothyroxine Tablets (VA-24-00084562)
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to solicit proposals for the procurement of Levothyroxine Sodium Tablets under Request for Proposal (RFP) 36E79724R0020. This procurement aims to secure an uninterrupted supply of these essential medications for various VA facilities, including Consolidated Mail Order Pharmacies, State Veterans Homes, the Indian Health Service, and the Federal Health Care Center. The contract will span one year, with the possibility of four additional pre-priced option periods, reflecting the VA's commitment to meeting the pharmaceutical needs of veterans. Interested suppliers must submit their proposals by September 30, 2024, and can direct inquiries to Contract Specialist Youlanda Duggar at Youlanda.duggar@va.gov or by phone at 708-786-4943.
    6505--Compounded Chemotherapy
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is soliciting quotes for a firm-fixed price Indefinite Quantity Indefinite Delivery (IDIQ) contract to supply compounded chemotherapy medications for the VA Long Beach Healthcare System in California. Vendors are required to provide a comprehensive list of specified chemotherapy drugs, ensuring compliance with safety and quality standards, including a minimum of 12 hours remaining on the Beyond-Use Date for all products. This procurement is crucial for maintaining effective patient care and access to essential medications, with the contract performance period expected to span from October 2024 through September 2029. Interested parties must submit their proposals by September 9, 2024, at 10:00 AM Pacific Time, and direct any inquiries to Hestia Sim at Hestia.Sim@va.gov.
    6505--Neuraceq - Radiopharmaceuticals
    Active
    Veterans Affairs, Department Of
    Special Notice: VETERANS AFFAIRS, DEPARTMENT OF is seeking a sole source procurement for Neuraceq - Radiopharmaceuticals. Neuraceq is a radioactive diagnostic agent used for Positron Emission Tomography (PET) imaging of the brain. It is used to estimate -amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. The procurement involves the preparation and delivery of F-18 Florbetaben (NeuraCeq) doses performed at a contractor facility and delivered to the PET/CT Service at VA Connecticut Healthcare in West Haven, CT. The deliveries will be made Monday through Friday between 7:00 am and 3:00 pm. Only vendors within a 60-mile radius of VA Connecticut need to respond to this RFQ.
    6505 -- SIR Y-90 Resin Microspheres Brand Name or Equal
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking a contractor to provide Yttrium-90 (Y-90) SIR-Spheres resin microspheres for cancer treatment at the VA Palo Alto Healthcare System. This procurement involves a sole source award to Sirtex Medical Inc., with the contract set to span from October 1, 2024, to September 30, 2025, requiring compliance with various regulatory standards for handling radioactive materials. The SIR-Spheres are critical for treating patients with unresectable cancers, ensuring safe and compliant delivery of these specialized medical supplies. Interested vendors may submit a capabilities statement to Derek L. Brown at derek.brown7@va.gov, with all responses considered at the discretion of the government.
    Teleradiology Services for VASNHCS
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is seeking proposals for Teleradiology Services for the Veterans Affairs Southern Nevada Health Care System (VASNHCS). The contract requires certified or board-eligible radiology physicians to provide remote diagnostic imaging services, including CT, MRI, and ultrasound scans, in accordance with strict American College of Radiology standards. This procurement is critical for ensuring timely and accurate diagnostic services for veterans, with an estimated total contract value of $19 million over the performance period from December 1, 2024, to November 30, 2029. Interested vendors should contact Maricela A Berrones-Gauger at maricela.berrones-gauger@va.gov for further details and to submit proposals, adhering to the Service-Disabled Veteran-Owned Small Business (SDVOSB) set-aside requirements.
    6505--Abiraterone Acetate Tablets
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) for the procurement of Abiraterone Acetate Tablets, identified by solicitation number 36E79724R0023. This procurement aims to secure a reliable supply of these pharmaceutical products for the VA, Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and other federal healthcare entities, emphasizing the need for uninterrupted supply and compliance with specific labeling and packaging requirements. The estimated annual requirements include 71,997 bottles of 120-count 250mg tablets and 1,102 bottles of 60-count 500mg tablets, with the RFP scheduled for electronic release on approximately September 18, 2024, and a closing date of October 2, 2024. Interested vendors can direct inquiries to Contract Specialist Richard Mahario at Richard.Mahario@va.gov or by phone at 708-786-5247, and must regularly check SAM.gov for updates as no paper copies of the solicitation will be provided.